Department of Microbiology, Techno India University, EM-4, Sector-V, Salt Lake City, Kolkata, 700091, India.
J Egypt Natl Canc Inst. 2022 Jun 20;34(1):26. doi: 10.1186/s43046-022-00127-2.
Cancer cells are different from normal cells in regard to phenotypic and functional expression. Cancer is the outcome of aberrant gene expression affecting various cellular signaling pathways. MicroRNAs (MiRs) are small, non-coding RNAs regulating the expression of various protein-coding genes post-transcriptionally and are known to play critical roles in the complicated cellular pathways leading to cell growth, proliferation, development, and apoptosis. MiRs are involved in various cancer-related pathways and function both as tumor suppressor and cancer-causing genes. There is a need for significant biomarkers, and better prognostication of response to a particular treatment and liquid biopsy could be useful to appraise such potential biomarkers. This review has focused on the involvement of anomalous expression of miRs in human pancreatic cancer and the investigation of miR-based biomarkers for disease diagnosis and better therapeutic selection.
癌细胞在表型和功能表达上与正常细胞不同。癌症是异常基因表达影响各种细胞信号通路的结果。microRNAs(miRs)是一种小的非编码 RNA,可在后转录水平调节各种蛋白编码基因的表达,已知其在导致细胞生长、增殖、发育和凋亡的复杂细胞途径中发挥关键作用。miRs 参与各种与癌症相关的途径,并作为肿瘤抑制基因和致癌基因发挥作用。因此,需要显著的生物标志物,对特定治疗反应的预后评估和液体活检可能有助于评估这些潜在的生物标志物。本综述重点讨论了异常表达的 miRs 在人类胰腺癌中的作用,以及基于 miR 的生物标志物在疾病诊断和更好的治疗选择方面的研究。